Search research articles
Contact Us
Filters
Showing results (161-170 of 217) with videos related to
Page
of 22
Sort By:
Hemasphere
|
September 21, 2023
High-throughput Proteomics Identifies THEMIS2 as Independent Biomarker of Treatment-free Survival in Untreated CLL
Paul J Hengeveld, P Martijn Kolijn, Jeroen A A Demmers, et al.
The Lancet. Oncology
|
November 9, 2023
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
Carsten U Niemann, Talha Munir, Carol Moreno, et al.
The Science of the Total Environment
|
October 31, 2025
Evaluation of low-density polyethylene degradation using a new thermophilic bacterial isolate
Mateus Manabu Abe, Carlos Eduardo Moraes, Marcos Vinícius Basaglia, et al.
Blood Advances
|
December 23, 2021
COVID-19 vaccination in patients with immune thrombocytopenia
Chantal Visser, Maurice Swinkels, Erik D van Werkhoven, et al.
Leukemia
|
May 18, 2022
Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21<sup>R110</sup>
Paul J Hengeveld, Y Emre Ertem, Julie M N Dubois, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2023
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study
Talha Munir, Carol Moreno, Carolyn Owen, et al.
Leukemia & Lymphoma
|
October 3, 2025
Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study
Nizar J Bahlis, Jeffrey Zonder, Lionel Karlin, et al.
Blood
|
September 15, 2018
Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib
Iris de Weerdt, Tom Hofland, Roeland Lameris, et al.
Haematologica
|
March 17, 2018
Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients
Laurens E Franssen, Inger S Nijhof, Suzana Couto, et al.
Leukemia & Lymphoma
|
June 23, 2022
Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group
Doreen G Te Raa, Lina van der Straten, Michel van Gelder, et al.
Page
of 22
Search research articles
Search
Showing results (161-170 of 217) with videos related to
Sort By:
Page
of 22
Hemasphere
|
September 21, 2023
High-throughput Proteomics Identifies THEMIS2 as Independent Biomarker of Treatment-free Survival in Untreated CLL
Paul J Hengeveld, P Martijn Kolijn, Jeroen A A Demmers, et al.
The Lancet. Oncology
|
November 9, 2023
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
Carsten U Niemann, Talha Munir, Carol Moreno, et al.
The Science of the Total Environment
|
October 31, 2025
Evaluation of low-density polyethylene degradation using a new thermophilic bacterial isolate
Mateus Manabu Abe, Carlos Eduardo Moraes, Marcos Vinícius Basaglia, et al.
Blood Advances
|
December 23, 2021
COVID-19 vaccination in patients with immune thrombocytopenia
Chantal Visser, Maurice Swinkels, Erik D van Werkhoven, et al.
Leukemia
|
May 18, 2022
Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21<sup>R110</sup>
Paul J Hengeveld, Y Emre Ertem, Julie M N Dubois, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2023
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study
Talha Munir, Carol Moreno, Carolyn Owen, et al.
Leukemia & Lymphoma
|
October 3, 2025
Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study
Nizar J Bahlis, Jeffrey Zonder, Lionel Karlin, et al.
Blood
|
September 15, 2018
Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib
Iris de Weerdt, Tom Hofland, Roeland Lameris, et al.
Haematologica
|
March 17, 2018
Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients
Laurens E Franssen, Inger S Nijhof, Suzana Couto, et al.
Leukemia & Lymphoma
|
June 23, 2022
Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group
Doreen G Te Raa, Lina van der Straten, Michel van Gelder, et al.
Page
of 22